The FDA updated the warnings on more HRT patches. Here’s what it means for you.

If you've been thinking about hormone therapy for menopause, or you already use an estrogen patch, you may have seen the headlines this week. On October 30, 2026, the U.S. Food and Drug Administration approved updated labeling for three estradiol transdermal patches, removing statements about cardiovascular disease, breast cancer, and probable dementia from the products' boxed warning (HHS/FDA announcement). At the same time, many women around New York are still struggling to fill their usual patch.

Here is what changed, what didn't, and how to think about whether hormone therapy (often called HRT or menopausal hormone therapy) is right for you.

What the FDA actually did

This is the latest step in a process that began in November 2025, when the FDA asked manufacturers to revise the boxed warnings on menopausal hormone therapy products. In February 2026, the agency approved similar labeling changes for six products. The October 30 action adds three estradiol patches, and the FDA says 29 drug companies have now submitted proposed label changes (HHS/FDA). The FDA keeps a running list of products with updated prescribing information on its website (FDA).

A few days earlier, on October 19, the FDA also approved the first generic version of a once-weekly patch that combines estradiol with a progestogen, for women who still have a uterus (FDA).

Not everyone agrees with how the label changes were made. Some researchers have criticized the FDA for acting without an advisory committee and for releasing few details about the evidence behind this week's decision (The Guardian). It's reasonable to hear both sides. Whatever a label says, the decision about hormone therapy should still be made one person at a time.

What didn't change: HRT is still a personal decision

A label update doesn't mean hormone therapy is right for everyone, and it doesn't mean the risks are gone. The Menopause Society, the leading professional group for menopause care, puts it this way: risks are low for younger, healthy women who start hormone therapy closer to menopause, and risks are greater when therapy is started at an older age or further from menopause onset (The Menopause Society). Its position statement describes hormone therapy as the most effective treatment for hot flashes and night sweats, and notes that it can help prevent bone loss (2022 position statement, PDF).

When I talk with a patient about HRT, we look at the whole picture:

• Your age and how long it has been since your last period. Timing matters.
• Your personal and family history. For example, blood clots, stroke, heart disease, migraine, liver disease, or breast or other hormone-sensitive cancers.
• Whether you still have a uterus. If you do, estrogen is paired with progesterone or a progestin to protect the uterine lining.
• The form of estrogen. Patches, gels, and sprays deliver estrogen through the skin, while pills are taken by mouth. The best route depends on your history and what you prefer day to day.
• Your goals. Relief from hot flashes and night sweats, better sleep, protecting your bones, or treating vaginal dryness and urinary symptoms (which low-dose vaginal estrogen can often treat locally).
• Non-hormonal options, if hormones aren't a fit or simply aren't your preference.

It also helps to rule out look-alikes. Fatigue, poor sleep, mood changes, and weight shifts can come from menopause, but they can also come from a thyroid problem, anemia, sleep apnea, or medication side effects. As an endocrinologist, I check for these, so you aren't treating the wrong thing.

Trouble finding your patch?

Demand for estradiol patches rose after the FDA's 2025 action. The FDA says the supply of approved patches has nearly doubled over the past year, but availability still varies by brand, strength, and pharmacy (FDA supply update). Reuters reported on October 28 that some injectable and vaginal estradiol products are now also in short supply, possibly as patients switch away from hard-to-find patches (Reuters via Investing.com).

If you can't fill your prescription:

1. Don't stop or change your hormone therapy on your own. Stopping suddenly can bring symptoms back, and switching needs the right dose.
2. Ask your pharmacist whether another FDA-approved estradiol patch, or a different strength, is in stock. Once-weekly and twice-weekly patches are changed on different schedules, so switching between them needs your prescriber's direction.
3. Talk with your prescriber about alternatives that may suit you, such as a gel, spray, or pill.

In my practice, I prescribe FDA-approved hormone therapy, including FDA-approved bioidentical estradiol and micronized progesterone when appropriate. Custom-compounded hormones have not been shown to be safer or more effective than FDA-approved products, and their dosing can be less consistent.

Don't forget your bones

Bone loss speeds up in the years around menopause. Estrogen helps protect bone, and some hormone therapy products are FDA-approved to help prevent postmenopausal osteoporosis. Hormone therapy isn't the only option, though, and it isn't the right bone treatment for everyone. If you have osteopenia, a past fracture, or a family history of hip fracture, it's worth reviewing your bone density and fracture risk alongside your menopause plan. You can read more about my approach to bone health and osteoporosis.

Getting a personalized HRT plan in NYC

You deserve time to ask every question. I'm a triple board-certified physician in Endocrinology, Internal Medicine, and Obesity Medicine, and I see patients in person on Thursdays at my office at 19 East 80th Street on the Upper East Side, by telehealth anywhere in New York and New Jersey, and through private home visits. I'm also one of the physicians who give talks in Meeting the Moment: An Educational Series on Menopause at Cambridge Chemists on the Upper East Side, because good information is where good decisions start.

A visit for menopause and HRT care includes a full review of your symptoms, cycle history, medications, and personal and family history. We weigh the benefits and risks of each option together, and you leave with a written plan. We work alongside your gynecologist and primary care doctor, and routine screenings such as mammograms continue with them.

Not sure where to start? New patients can book a free 15-minute discovery call to learn how the practice works and whether it's a good fit. (The call is an introduction, not a medical visit, so no medical advice is given.) Ready for a full consultation? Book a visit or see our fees and FAQ.

New to the practice?

Start with a free 15-minute conversation.

An introduction to how care works here. No medical advice is given on the call.

Book a free discovery call ↗ Book a visit

Medical disclaimer: This article is for general education only. It is not medical advice and does not create a doctor-patient relationship. Hormone therapy isn't right for everyone, and benefits, risks, and results vary from person to person. Talk with your own healthcare provider before starting, stopping, or changing any medication. If you are having a medical emergency, call 911. This article is not sponsored and does not endorse any specific product.

Sources

1. U.S. Department of Health and Human Services. "Trump Administration Delivers for Women with Major Advances in Menopause Care." October 30, 2026. https://www.hhs.gov/press-room/fda-advances-menopause-care-hormone-therapy-labeling-access.html
2. U.S. Food and Drug Administration. "Menopausal Hormone Therapies with Updated Prescribing Information." Content current as of October 30, 2026. https://www.fda.gov/drugs/drug-safety-and-availability/menopausal-hormone-therapies-updated-prescribing-information
3. U.S. Food and Drug Administration. "FDA Approves Once-Weekly Generic Hormone Therapy Patch for Women." October 20, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-once-weekly-generic-hormone-therapy-patch-women
4. U.S. Food and Drug Administration. "FDA Update on Estradiol Transdermal Patch Availability." September 3, 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-update-estradiol-transdermal-patch-availability
5. Schreiber, M. "FDA again bypasses advisers to remove black-box warnings from menopause treatments." The Guardian, October 30, 2026. https://www.theguardian.com/us-news/2026/oct/30/fda-remove-warnings-menopause-treatments
6. Roy, M. "US estrogen supply crunch widens as women seek alternatives to scarce patches." Reuters (via Investing.com), October 28, 2026. https://www.investing.com/news/stock-market-news/us-estrogen-supply-crunch-widens-as-women-seek-alternatives-to-scarce-patches-4978221
7. The Menopause Society. "The Menopause Society Comments on the FDA Announcement on Hormone Therapy." November 10, 2025. https://menopause.org/press-releases/the-menopause-society-comments-on-the-fda-announcement-on-hormone-therapy
8. The North American Menopause Society. "The 2022 hormone therapy position statement." https://menopause.org/wp-content/uploads/professional/nams-2022-hormone-therapy-position-statement.pdf